252 related articles for article (PubMed ID: 23849326)
21. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures.
Piña-Garza JE; Espinoza R; Nordli D; Bennett DA; Spirito S; Stites TE; Tang D; Sturm Y
Neurology; 2005 Nov; 65(9):1370-5. PubMed ID: 16275822
[TBL] [Abstract][Full Text] [Related]
22. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E
Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613
[TBL] [Abstract][Full Text] [Related]
23. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.
Ortenzi A; Paggi A; Foschi N; Sabbatini D; Pistoli E
Funct Neurol; 2008; 23(2):97-100. PubMed ID: 18671911
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy.
Jang Y; Yoon S; Kim TJ; Lee S; Yu KS; Jang IJ; Chu K; Lee SK
Sci Rep; 2021 Mar; 11(1):6370. PubMed ID: 33737678
[TBL] [Abstract][Full Text] [Related]
25. Feasibility and pharmacokinetics of carbamazepine oral loading doses.
Cohen H; Howland MA; Luciano DJ; Rubin RN; Kutt H; Hoffman RS; Leung LK; Devinsky O; Goldfrank LR
Am J Health Syst Pharm; 1998 Jun; 55(11):1134-40. PubMed ID: 9626375
[TBL] [Abstract][Full Text] [Related]
26. Tolerability and efficacy of oral loading of levetiracetam.
Koubeissi MZ; Amina S; Pita I; Bergey GK; Werz MA
Neurology; 2008 May; 70(22 Pt 2):2166-70. PubMed ID: 18505995
[TBL] [Abstract][Full Text] [Related]
27. Plasma level monitoring of oxcarbazepine in epileptic patients.
González-Esquivel DF; Ortega-Gavilán M; Alcántara-López G; Jung-Cook H
Arch Med Res; 2000; 31(2):202-5. PubMed ID: 10880728
[TBL] [Abstract][Full Text] [Related]
28. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
Pisani F; Fazio A; Oteri G; Artesi C; Xiao B; Perucca E; Di Perri R
Acta Neurol Scand; 1994 Aug; 90(2):130-2. PubMed ID: 7801739
[TBL] [Abstract][Full Text] [Related]
29. Long-term use of oxcarbazepine oral suspension in childhood epilepsy: open-label study.
Rufo-Campos M; Casas-Fernández C; Martínez-Bermejo A
J Child Neurol; 2006 Jun; 21(6):480-5. PubMed ID: 16948931
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic drug monitoring of oxcarbazepine].
Bouquié R; Dailly E; Bentué-Ferrer D;
Therapie; 2010; 65(1):61-5. PubMed ID: 20205998
[TBL] [Abstract][Full Text] [Related]
31. Severe overdosage with the antiepileptic drug oxcarbazepine.
van Opstal JM; Janknegt R; Cilissen J; L'Ortije WH; Nel JE; De Heer F
Br J Clin Pharmacol; 2004 Sep; 58(3):329-31. PubMed ID: 15327594
[TBL] [Abstract][Full Text] [Related]
32. Rapid oral loading of carbamazepine in the emergency department.
Purcell TB; McPheeters RA; Feil M; Chavez R
Ann Emerg Med; 2007 Aug; 50(2):121-6. PubMed ID: 17643851
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic drug interactions in children taking oxcarbazepine.
Sallas WM; Milosavljev S; D'souza J; Hossain M
Clin Pharmacol Ther; 2003 Aug; 74(2):138-49. PubMed ID: 12891224
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures.
Fountain NB; Krauss G; Isojarvi J; Dilley D; Doty P; Rudd GD
Epilepsia; 2013 Jan; 54(1):58-65. PubMed ID: 22708895
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
Yu Y; Zhang Q; Xu W; Lv C; Hao G
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
[TBL] [Abstract][Full Text] [Related]
36. Oxcarbazepine, an antiepileptic agent.
Kalis MM; Huff NA
Clin Ther; 2001 May; 23(5):680-700; discussion 645. PubMed ID: 11394728
[TBL] [Abstract][Full Text] [Related]
37. Overview of the clinical pharmacokinetics of oxcarbazepine.
Flesch G
Clin Drug Investig; 2004; 24(4):185-203. PubMed ID: 17516704
[TBL] [Abstract][Full Text] [Related]
38. Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.
Clinckers R; Smolders I; Michotte Y; Ebinger G; Danhof M; Voskuyl RA; Della Pasqua O
Br J Pharmacol; 2008 Dec; 155(7):1127-38. PubMed ID: 18836479
[TBL] [Abstract][Full Text] [Related]
39. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers.
Degen PH; Flesch G; Cardot JM; Czendlik C; Dieterle W
Biopharm Drug Dispos; 1994 Aug; 15(6):519-26. PubMed ID: 7993989
[TBL] [Abstract][Full Text] [Related]
40. Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages.
Steinhoff BJ; Wendling AS
Epilepsy Res; 2009 Dec; 87(2-3):256-9. PubMed ID: 19850448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
